LASSBio-468: A new achiral thalidomide analogue which modulates TNF-α and NO production and inhibits endotoxic shock and arthritis in an animal model

International Immunopharmacology

Volumn 5, Issue 3, 2005, Pages 485-494

  Alexandre Moreira, Magna S ^a,b   Takiya, Christina M ^a   De Arruda, Luciana B ^a   Pascarelli, Bernardo ^a   Gomes, Raquel N ^c   Castro Faria Neto, Hugo C ^c   Lima, Lídia M ^a   Barreiro, Eliezer J ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Endotoxic shock; LASSBio 468; LPS; NO; TNF

Indexed keywords

2 [4 (1,4 THIAZINAN 4 YLSULFONYL)PHENYL] 1,3 ISOINDOLINEDIONE; LIPOPOLYSACCHARIDE; NITRIC OXIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; HISTOPATHOLOGY; IMMUNOREGULATION; INHIBITION KINETICS; LETHAL DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; SEPTIC SHOCK;

EID: 15944421269     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2004.10.017     Document Type: Article

References (34)

1. M. Pasparakis, L. Alexopoulou, V. Episkopou, and G. Kollias Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response J. Exp. Med. 184 1996 1397 1411
2. J.A. Barbara, X. Van ostade, and A. Lopez Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective Immunol. Cell Biol. 74 1996 434 443
3. K.J. Tracey TNF and Mae West or: death from too much of a good thing Lancet 345 1995 75 76
4. K.J. Tracey, and A. Cerami Tumor necrosis factor: a pleiotropic cytokine and therapeutic target Annu. Rev. Med. 1994 491 503
5. K. Pfeffer, T. Matsuyama, T.M. Kundig, A. Wakeham, K. Kishihara, and A. Shahinian Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection Cell 73 1993 457 467
6. J. Rothe, W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, and F. Kontgen Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes Nature 364 1993 798 802
7. B.E. Turk, H. Jiang, and J.O. Liu Binding of thalidomide to alpha 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor production Proc. Natl. Acad. Sci. U. S. A. 93 1996 7226 7552
8. L. Calabrese, and A.B. Fleischer Thalidomide: current and potential clinical applications Am. J. Med. 15 108 2000 487 495
9. E.P. Sampaio, E.N. Sarno, R. Galilly, Z.A. Cohn, and G. Kaplan Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes J. Exp. Med. 173 1991 699 703
10. A.L. Moriera, E.P. Sampaio, A. Zmuidzinas, P. Frindt, K.A. Smith, and G. Kaplan Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation J. Exp. Med. 177 1993 1675 1680
11. I.D. Klausner, V.H. Freedman, and G. Kaplan Thalidomide as an anti-TNF-α: inhibitor: implications for clinical use Clin. Immunol. Immunopathol. 81 1996 219 223
12. L.M. Lima, P. Castro, A.L. Machado, C.A.M. Fraga, C. Lugnier, and V.L. de Moraes Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues Bioorg. Med. Chem. 10 2002 3067 3073
13. M. Zimmerman Ethical guidelines for investigation of experimental pain in conscious animals Pain 16 1983 109 110
14. A.M. Badger, D. Olivera, J.E. Talmadge, and N. Hanna Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action Circ. Shock 27 1989 51 61
15. K. Green, D. Wagner, J. Glogowski, P. Skipper, J. Wishnock, and S. Tannenbaum Analysis of nitrate, nitrite and (l5N) nitrate in biological fluids Ann. Biochem. 126 1982 131 138
16. B.B. Newbould Chemotherapy of arthritis induced in rats by mycobacterial adjuvant Br. J. Pharmacol. Chemother. 21 1963 127 136
17. S.L. Reineer, S. Zheng, D.B. Corry, and R. Locksley Constructing polycompetitor cDNAs for quantitative PCR J. Immunol. Methods 165 1993 37 46
18. M.P. Reddy, E.F. Webb, D. Cassat, D. Maley, J.C. Lee, and D.E. Griswold Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses Int. J. Immunopharmacol. 16 1994 795 804
19. W. Lenz Thalidomide and congenital anomalies Lancet 1962 1 45
20. S. Tseng, G. Pak, K. Washenik, M.K. Pomeranz, and J.L. Shupack Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses J. Am. Acad. Dermatol. 35 1996 969 979
21. D.I. Stirling Pharmacology of thalidomide Semin. Hematol. 37 2000 5 14
22. R.J. D'Amato, M.S. Loughran, and E. Flynn Thalidomideis an inhibitor of angiogenesis Proc. Natl. Acad. Sci. U. S. A. 91 1994 4082 4085
23. B.M. Kenyon, F. Browne, and R.J. D'Amato Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization Exp. Eye Res. 64 1997 971 978
24. K. Podar, Y.T. Tai, F.E. Davies, S. Lentzsch, M. Sattler, and T. Hideshima Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration Blood 98 2001 428 435
25. B. Beutler, I.W. Milsark, and A.C. Cerami Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin Science 229 1985 869 871
26. G. Hasko, C. Szabo, Z.H. Ne_eth, B. Lendvai, and E.S. Vizi Modulation by dantroiene of endotoxin-induced Interleukin-10, tumor necrosis factor-alpha and nitric oxide production in vivo and in vitro Br. J. Pharmacol. 124 1998 1099 1106
27. Z.H. Nemeth, G. Hasko, and E.S. Vizi Pyrrolidine dithiocarbamate augments IL-10, inhibits TNF-α, MIP-1 α, IL-12, and nitric oxide production and protects from the lethal effect of endotoxin Shock 10 1998 49 53
28. A. Marchant, Z. Amraoui, C. Gueydan, C. Bruyns, O. Le Moine, and P. Vandenabeele Methylprednisolone differentially regulates IL-10 and tumour necrosis factor (TNF) production during murine endotoxemia Clin. Exp. Immunol. 106 1996 91 96
29. A. Eigler, B. Siegmund, U. Emmerich, K.H. Baumann, G. Hartmann, and S. Endres Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production J. Leukoc. Biol. 63 1998 101 107
30. S.L. Kunkel, N.W. Lukas, R.M. Strieter, and S.W. Chenseu Th1 and Th2 response regulate experimental lung granuloma development Sarcoidosis Vasc. Diffuse Lung Dis. 13 1996 120 128
31. A. Lanzavecchia, and F. Sallusto Antigen decoding by T lymphocytes> from synapses to fate determination Nat. Immunol. 2001 487 492
32. A. Sher, and R.L. Coffman Regulation of immunity to parasites by T cell and T cell-derived cytokines Annu. Rev. Immunol. 10 1992 385 409
33. S.W. Chensue, K. Warmington, J. Ruth, P. Lincoln, M.C. Kuo, and S.L. Kunkel Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor Am. J. Pathol. 145 1994 1105 1113
34. B. Qiu, K.A. Frait, F. Reich, E. Komuniecki, and S.W. Chenseu Chemokine expression dynamics in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation Am. J. Pathol. 158 2001 1503 1515